Advanced search

Vol 15, No 5 (2019)
Review paper
Published online: 2019-09-05

open access

View PDF Download PDF file
Page views 1754
Article views/downloads 1434
Get Citation

Connect on Social Media

Connect on Social Media

Characteristics of in vitro model systems for ovarian cancer studies

Patrycja Tudrej1, Katarzyna Aleksandra Kujawa1, Alexander Jorge Cortez1, Katarzyna Marta Lisowska1
DOI: 10.5603/OCP.2019.0024
Oncol Clin Pract 2019;15(5):246-259.

Abstract

Nowadays, targeted therapy plays a growing role in oncological treatment. In ovarian cancer, particularly promising results are achieved with poly (ADP-ribose) polymerase (PARP) inhibitors. Recent clinical trials have shown that PARP inhibitors can result in significantly longer progression-free survival. These results encourage the search for other targeted therapies and bring hope that ovarian cancer can soon become a manageable chronic disease. The main problem in ovarian cancer research is the heterogeneity of this disease. Recent studies have shown that different histological types of ovarian cancer can originate from distinct tissues. According to the recent knowledge, “ovarian cancer” is an artificial term for distinct invasive malignancies localised within the pelvis. Genetic and immunophenotype analyses have shown that high-grade serous ovarian cancer, the most frequent histological type and the one with the worst prognosis, originates mainly from fallopian tube epithelium, while endometrioid and clear-cell cancers originate from the endometrium. For these reasons, in basic and preclinical studies on ovarian cancer, one has to carefully choose a well-defined model system, corresponding to the histological type of interest. In this article, we discuss ovarian cancer cell lines most frequently used in in vitro studies. Our aim is to indicate the advantages and disadvantages of different models, encompassing primary and established cell cultures, two- and three-dimensional models, etc. In particular, we would like to alert researchers to the fact that the most popular cell lines SKOV3 and A2780 do not represent a suitable model for studies on high-grade serous ovarian cancer.

Keywords: ovarian cancerin vitro modelsovarian cancer cell lines3D cell culturehigh-grade serous ovarian cancerchemoresistance

Article available in PDF format

View PDF Download PDF file

References

  1. Cortez AJ, Tudrej P, Kujawa KA, et al. Advances in ovarian cancer therapy. Cancer Chemother Pharmacol. 2018; 81(1): 17–38.
    CrossRefPubMed
  2. Lee JY, Kim S, Kim YT, et al. Changes in ovarian cancer survival during the 20 years before the era of targeted therapy. BMC Cancer. 2018; 18: 1–8.
    CrossRefPubMed
  3. Dubeau L. The cell of origin of ovarian epithelial tumors and the ovarian surface epithelium dogma: does the emperor have no clothes? Gynecol Oncol. 1999; 72(3): 437–442.
    CrossRefPubMed
  4. Dubeau L. The cell of origin of ovarian epithelial tumours. Lancet Oncol. 2008; 9(12): 1191–1197.
    CrossRefPubMed
  5. Kujawa KA, Lisowska KM. Ovarian cancer — from biology to clinic. Postepy Hig Med Dosw (Online). 2015; 69: 1275–1290.
    PubMed
  6. Cobb LP, Gaillard S, Wang Y, et al. Adenocarcinoma of Mullerian origin: review of pathogenesis, molecular biology, and emerging treatment paradigms. Gynecol Oncol Res Pract. 2015; 2: 1–16.
    CrossRefPubMed
  7. Shih IM, Kurman R. Ovarian tumorigenesis — A proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004; 164(5): 1511–1518.
    CrossRef
  8. Creative Bioarray: Immortalized human fallopian tube secretory epithelial cells (FT33-shp53-R24C). Available online: https://www.creative-bioarray.com/immortalized-human-fallopian-tube-secretory-epithelial-cells-ft33-shp53-r24c-cat-csc-i9204l-item-2114.htm (accessed on 2019-03-14).
  9. Life Line Cell Technology: Fallopian tube epithelial cells. Available online: https://www.lifelinecelltech.com/shop/tissue-type/reproductive-tissue/fallopian-tube-epithelial-cells-fc-0081/ (accessed on 2019-03-13).
  10. ScienCell Research Laboratories: Human Ovarian Surface Epithelial Cells. Available online: https://www.sciencellonline.com/human-ovarian-surface-epithelial-cells.html (accessed on 2019-03-14).
  11. Applied Biological Materials: Human Primary Ovarian Surface Epithelial Cells. Available online: https://www.abmgood.com/Human-Primary-Ovarian-Surface-Epithelial-Cells-T4198.html (accessed on 2019-03-14).
  12. Sasaki R, Narisawa-Saito M, Yugawa T, et al. Oncogenic transformation of human ovarian surface epithelial cells with defined cellular oncogenes. Carcinogenesis. 2009; 30(3): 423–431.
    CrossRefPubMed
  13. Gjyshi A, Dash S, Cen L, et al. Early transcriptional response of human ovarian and fallopian tube surface epithelial cells to norepinephrine. Sci Rep. 2018; 8: 1–11.
    CrossRefPubMed
  14. Auersperg N, Pan J, Grove BD, et al. E-cadherin induces mesenchymal-to-epithelial transition in human ovarian surface epithelium. Proc Natl Acad Sci U S A. 1999; 96(11): 6249–6254.
    CrossRefPubMed
  15. Li NF, Broad S, Lu YJ, et al. Human ovarian surface epithelial cells immortalized with hTERT maintain functional pRb and p53 expression. Cell Prolif. 2007; 40(5): 780–794.
    CrossRefPubMed
  16. Lawrenson K, Benjamin E, Turmaine M, et al. In vitro three-dimensional modelling of human ovarian surface epithelial cells. Cell Prolif. 2009; 42(3): 385–393.
    CrossRefPubMed
  17. Lee YL, Lee KF, Xu JS, et al. Establishment and characterization of an immortalized human oviductal cell line. Mol Reprod Dev. 2001; 59(4): 400–409.
    CrossRefPubMed
  18. Kuhn ET. Rimondi E, Secchiero P. Current preclinical models of ovarian cancer. J Carcinog Mutagen. 2015; 6(2): 1–9.
    CrossRef
  19. Tudrej P, Olbryt M, Zembala-Nożyńska E, et al. Establishment and characterization of the novel high-grade serous ovarian cancer cell line OVPA8. Int J Mol Sci. 2018; 19(7): 1–26.
    CrossRefPubMed
  20. Ince TA, Sousa AD, Jones MA, et al. Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours. Nat Commun. 2015; 6: 1–14.
    CrossRefPubMed
  21. National Cancer Institute: Cell lines in the in vitro Screen. Available online: https://dtp.cancer.gov/discovery_development/nci-60/cell_list.htm (accessed on 15.03.2019).
  22. Ellison G, Klinowska T, Westwood RFR, et al. Further evidence to support the melanocytic origin of MDA-MB-435. Mol Pathol. 2002; 55(5): 294–299.
    CrossRefPubMed
  23. Rae JM, Creighton CJ, Meck JM, et al. MDA-MB-435 cells are derived from M14 melanoma cells — a loss for breast cancer, but a boon for melanoma research. Breast Cancer Res Treat. 2007; 104(1): 13–19.
    CrossRefPubMed
  24. Chambers AF. MDA-MB-435 and M14 cell lines: identical but not M14 melanoma? Cancer Res. 2009; 69(13): 5292–5293.
    CrossRefPubMed
  25. Roschke AV, Tonon G, Gehlhaus KS, et al. Karyotypic complexity of the NCI-60 drug-screening panel. Cancer Res. 2003; 63(24): 8634–8647.
    PubMed
  26. Gartler SM. Apparent Hela cell contamination of human heteroploid cell lines. Nature. 1968; 217(5130): 750–751.
    CrossRefPubMed
  27. Fogh J, Wright WC, Loveless JD. Absence of Hela cell contamination in 169 cell lines derived from human tumors. J Natl Cancer Inst. 1977; 58(2): 209–214.
    CrossRefPubMed
  28. Anglesio MS, Wiegand KC, Melnyk N, et al. Type-specific cell line models for type-specific ovarian cancer research. PLoS One. 2013; 8(9): e72162.
    CrossRefPubMed
  29. Domcke S, Sinha R, Levine DA, et al. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun. 2013; 4: 1–10.
    CrossRefPubMed
  30. Beaufort CM, Helmijr JCA, Piskorz AM, et al. Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes. PLoS One. 2014; 9(9): 1–16.
    CrossRefPubMed
  31. Fogh J, Trempe G. New human tumor cell lines. Human Tumor Cells in Vitro. 1975: 115–159.
    CrossRef
  32. Hamilton TC, Young RC, Ozols RF. Experimental-model systems of ovarian-cancer — applications to the design and evaluation of new treatment approaches. Semin Oncol. 1984; 11(3): 285–298. .
    PubMed
  33. Shaw TJ, Senterman MK, Dawson K, et al. Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer. Mol Ther. 2004; 10(6): 1032–1042.
    CrossRefPubMed
  34. Lee JM, Mhawech-Fauceglia P, Lee N, et al. A three-dimensional microenvironment alters protein expression and chemosensitivity of epithelial ovarian cancer cells in vitro. Lab Invest. 2013; 93(5): 528–542.
    CrossRefPubMed
  35. Lau DHM, Lewis AD, Ehsan MN, et al. Multifactorial mechanisms associated with broad cross-resistance of ovarian-carcinoma cells selected by cyanomorpholino doxorubicin. Cancer Res. 1991; 51(19): 5181–5187. .
    PubMed
  36. Wilson AP. Characterization of a cell line derived from the ascites of a patient with papillary serous cystadenocarcinoma of the ovary. J Natl Cancer Inst. 1984; 72(3): 513–521.
    PubMed
  37. Ikediobi ON, Davies H, Bignell G, et al. Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol Cancer Ther. 2006; 5(11): 2606–2612.
    CrossRefPubMed
  38. Elias KM, Emori MM, Papp E, et al. Beyond genomics: critical evaluation of cell line utility for ovarian cancer research. Gynecol Oncol. 2015; 139(1): 97–103.
    CrossRefPubMed
  39. Hew KE, Miller PC, El-Ashry D, et al. MAPK activation predicts poor outcome and the MEK inhibitor, selumetinib, reverses antiestrogen resistance in er-positive high-grade serous ovarian cancer. Clin Cancer Res. 2016; 22(4): 935–947.
    CrossRefPubMed
  40. Witt AE, Lee CW, Lee TI, et al. Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer. Oncogene. 2017; 36(12): 1707–1720.
    CrossRefPubMed
  41. Landini I, Lapucci A, Pratesi A, et al. Selection and characterization of a human ovarian cancer cell line resistant to auranofin. Oncotarget. 2017; 8(56): 96062–96078.
    CrossRefPubMed
  42. Behrens BC, Hamilton TC, Masuda H, et al. Characterization of a cis-diamminedichloroplatinum(Ii)-resistant human ovarian-cancer cell-line and its use in evaluation of platinum analogs. Cancer Res. 1987; 47(2): 414–418. .
    PubMed
  43. Masuda H, Ozols RF, Lai GM, et al. Increased DNA-repair as a mechanism of acquired-resistance to cis-diamminedichloroplatinum(Ii) in human ovarian-cancer cell-lines. Cancer Res. 1988; 48(20): 5713–5716. .
    PubMed
  44. Januchowski R, Zawierucha P, Ruciński M, et al. Drug transporter expression profiling in chemoresistant variants of the A2780 ovarian cancer cell line. Biomed Pharmacother. 2014; 68(4): 447–453.
    CrossRefPubMed
  45. Sak K. In vitro cytotoxic activity of flavonoids on human ovarian cancer cell lines. Cancer Science & Research: Open Access. 2015; 2(1): 1–13.
    CrossRef
  46. Sun Si, Zhao S, Yang Q, et al. Enhancer of zeste homolog 2 promotes cisplatin resistance by reducing cellular platinum accumulation. Cancer Sci. 2018; 109(6): 1853–1864.
    CrossRefPubMed
  47. ECACC General Cancer Collection: A2780ADR. Available online: https://www.phe-culturecollections.org.uk/products/celllines/generalcell/detail.jsp?refId=93112520&collection=ecacc_gc (accessed on 2019-03-15).
  48. Han X, DU F, Jiang Li, et al. A2780 human ovarian cancer cells with acquired paclitaxel resistance display cancer stem cell properties. Oncol Lett. 2013; 6(5): 1295–1298.
    CrossRefPubMed
  49. Resistant Cancer Cell Line Collection. Available online: http://www.wass-michaelislab.org/drug.php?drug=cisplatin (accessed on 2019-03-15).
  50. Jazaeri AA, Shibata E, Park J, et al. Overcoming platinum resistance in preclinical models of ovarian cancer using the neddylation inhibitor MLN4924. Mol Cancer Ther. 2013; 12(10): 1958–1967.
    CrossRefPubMed
  51. Ho CM, Lee FK, Huang SH, et al. Everolimus following 5-aza-2-deoxycytidine is a promising therapy in paclitaxel-resistant clear cell carcinoma of the ovary. Am J Cancer Res. 2018; 8(1): 56–69. .
    PubMed
  52. Perego P, Giarola M, Righetti SC, et al. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res. 1996; 56(3): 556–562. .
    PubMed
  53. Stewart JJ, White JT, Yan X, et al. Proteins associated with csplatin resistance in ovarian cancer cells identified by quantitative proteomic technology and integrated with mRNA expression levels. Mol Cell Proteomics. 2006; 5(3): 433–443.
    CrossRefPubMed
  54. Stordal B, Hamon M, McEneaney V, et al. Resistance to paclitaxel in a cisplatin-resistant ovarian cancer cell line is mediated by P-glycoprotein. PLoS One. 2012; 7(7): 1–13.
    CrossRefPubMed
  55. Benedetti V, Perego P, Beretta GL, et al. Modulation of survival pathways in ovarian carcinoma cell lines resistant to platinum compounds. Mol Cancer Ther. 2008; 7(3): 679–687.
    CrossRefPubMed
  56. Maliepaard M, van Gastelen MA, de Jong LA, et al. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res. 1999; 59(18): 4559–4563.
    PubMed
  57. Judson PL, Al Sawah E, Marchion DC, et al. Characterizing the efficacy of fermented wheat germ extract against ovarian cancer and defining the genomic basis of its activity. Int J Gynecol Cancer. 2012; 22(6): 960–967.
    CrossRefPubMed
  58. Redmond A, Moran E, Clynes M. Multiple drug resistance in the human ovarian carcinoma cell line OAW42-A. Eur J Cancer. 1993; 29A(8): 1078–1081.
    PubMed
  59. Sherman-Baust CA, Becker KG, Wood Iii WH, et al. Gene expression and pathway analysis of ovarian cancer cells selected for resistance to cisplatin, paclitaxel, or doxorubicin. J Ovarian Res. 2011; 4(1): 1–11.
    CrossRefPubMed
  60. Liu Y, Han S, Li Y, et al. MicroRNA-20a contributes to cisplatin-resistance and migration of OVCAR3 ovarian cancer cell line. Oncol Lett. 2017; 14(2): 1780–1786.
    CrossRefPubMed
  61. Macleod K, Mullen P, Sewell J, et al. Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer. Cancer Res. 2005; 65(15): 6789–6800.
    CrossRefPubMed
  62. Yu DH, Wolf JK, Scanlon M, et al. Enhanced C-Erbb-2/Neu expression in human ovarian-cancer cells correlates with more severe malignancy that can be suppressed by E1a. Cancer Res. 1993; 53(4): 891–898. .
    PubMed
  63. Yan XD, Li M, Yuan Y, et al. Biological comparison of ovarian cancer resistant cell lines to cisplatin and taxol by two different administrations. Oncol Rep. 2007; 17(5): 1163–1169. .
    PubMed
  64. Kubota N, Nishio K, Takeda Y, et al. Characterization of an etoposide-resistant human ovarian cancer cell line. Cancer Chemoth Pharm. 1994; 34(3): 183–190.
    CrossRef
  65. Li L, Luan YZ, Wang GD, et al. Development and characterization of five cell models for chemoresistance studies of human ovarian carcinoma. Int J Mol Med. 2004; 14(2): 257–264. .
    PubMed
  66. Lee C. Overexpression of Tyro3 receptor tyrosine kinase leads to the acquisition of taxol resistance in ovarian cancer cells. Mol Med Rep. 2015; 12(1): 1485–1492.
    CrossRefPubMed
  67. Bradley G, Naik M, Ling V. P-glycoprotein expression in multidrug-resistant human ovarian-carcinoma cell-lines. Cancer Res. 1989; 49(10): 2790–2796. .
    PubMed
  68. Leung CS, Yeung TL, Yip KP, et al. Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance. J Clin Invest. 2018; 128(2): 589–606.
    CrossRefPubMed
  69. Dasari S, Fang Y, Mitra AK. Cancer associated fibroblasts: naughty neighbors that drive ovarian cancer progression. Cancers (Basel). 2018; 10(11): 1–18.
    CrossRefPubMed
  70. Januchowski R, Zawierucha P, Ruciński M, et al. Microarray-based detection and expression analysis of extracellular matrix proteins in drug‑resistant ovarian cancer cell lines. Oncol Rep. 2014; 32(5): 1981–1990.
    CrossRefPubMed
  71. Wu YH, Chang TH, Huang YF, et al. COL11A1 confers chemoresistance on ovarian cancer cells through the activation of Akt/c/EBPβ pathway and PDK1 stabilization. Oncotarget. 2015; 6(27): 23748–23763.
    CrossRefPubMed
  72. Cornelison R, Llaneza DC, Landen CN. Emerging therapeutics to overcome chemoresistance in epithelial ovarian cancer: a mini-review. Int J Mol Sci. 2017; 18(10): 1–20.
    CrossRefPubMed
  73. Roy L, Cowden Dahl KD. Can stemness and chemoresistance be therapeutically targeted via signaling pathways in ovarian cancer? Cancers (Basel). 2018; 10(8): 1–23.
    CrossRefPubMed
  74. Suh D, Kim MK, Kim H, et al. Epigenetic therapies as a promising strategy for overcoming chemoresistance in epithelial ovarian cancer. Journal of Cancer Prevention. 2013; 18(3): 227–234.
    CrossRef
  75. Smith HJ, Straughn JM, Buchsbaum DJ, et al. Epigenetic therapy for the treatment of epithelial ovarian cancer: A clinical review. Gynecol Oncol Rep. 2017; 20: 81–86.
    CrossRefPubMed
  76. Moufarrij S, Dandapani M, Arthofer E, et al. Epigenetic therapy for ovarian cancer: promise and progress. Clin Epigenetics. 2019; 11(1): 7.
    CrossRefPubMed
  77. Lisowska KM, Olbryt M, Student S, et al. Unsupervised analysis reveals two molecular subgroups of serous ovarian cancer with distinct gene expression profiles and survival. J Cancer Res Clin Oncol. 2016; 142(6): 1239–1252.
    CrossRefPubMed
  78. Lisowska KM, Olbryt M, Dudaladava V, et al. Gene expression analysis in ovarian cancer — faults and hints from DNA microarray study. Front Oncol. 2014; 4: 1–11.
    CrossRefPubMed
  79. Konecny GE, Winterhoff B, Wang C. Gene-expression signatures in ovarian cancer: Promise and challenges for patient stratification. Gynecol Oncol. 2016; 141(2): 379–385.
    CrossRefPubMed
  80. Lupia M, Cavallaro U. Ovarian cancer stem cells: still an elusive entity? Mol Cancer. 2017; 16(1): 64.
    CrossRefPubMed
  81. Klemba A, Purzycka-Olewiecka JK, Wcisło G, et al. Surface markers of cancer stem-like cells of ovarian cancer and their clinical relevance. Contemp Oncol (Pozn). 2018; 22(1A): 48–55.
    CrossRefPubMed
  82. Ottevanger PB. Ovarian cancer stem cells more questions than answers. Semin Cancer Biol. 2017; 44: 67–71.
    CrossRefPubMed
  83. Luo X, Dong Z, Chen Y, et al. Enrichment of ovarian cancer stem-like cells is associated with epithelial to mesenchymal transition through an miRNA-activated AKT pathway. Cell Prolif. 2013; 46(4): 436–446.
    CrossRefPubMed
  84. Nowicka A, Marini FC, Solley TN, et al. Human omental-derived adipose stem cells increase ovarian cancer proliferation, migration, and chemoresistance. PLoS One. 2013; 8(12): e81859.
    CrossRefPubMed
  85. Coffman LG, Pearson AT, Frisbie LG, et al. Ovarian Carcinoma-Associated Mesenchymal Stem Cells Arise from Tissue-Specific Normal Stroma. Stem Cells. 2019; 37(2): 257–269.
    CrossRefPubMed
  86. Coffman LG, Choi YJ, McLean K, et al. Human carcinoma-associated mesenchymal stem cells promote ovarian cancer chemotherapy resistance via a BMP4/HH signaling loop. Oncotarget. 2016; 7(6): 6916–6932.
    CrossRefPubMed
  87. Klopp AH, Gupta A, Spaeth E, et al. Concise review: Dissecting a discrepancy in the literature: do mesenchymal stem cells support or suppress tumor growth? Stem Cells. 2011; 29(1): 11–19.
    CrossRefPubMed
  88. Bernardo AD, Thorsteinsdóttir S, Mummery CL. Advantages of the avian model for human ovarian cancer. Mol Clin Oncol. 2015; 3(6): 1191–1198.
    CrossRefPubMed
  89. Kitel R, Czarnecka J, Rusin A. Three-dimensional cell cultures. Applications in basic science and biotechnology. Postepy Bochemii. 2013; 59(3): 305–314. .
    PubMed
  90. Yamada KM, Cukierman E. Modeling tissue morphogenesis and cancer in 3D. Cell. 2007; 130(4): 601–610.
    CrossRefPubMed
  91. Heredia-Soto V, Redondo A, Berjón A, et al. High-throughput 3-dimensional culture of epithelial ovarian cancer cells as preclinical model of disease. Oncotarget. 2018; 9(31): 21893–21903.
    CrossRefPubMed
  92. Barbolina MV, Adley BP, Ariztia EV, et al. Microenvironmental regulation of membrane type 1 matrix metalloproteinase activity in ovarian carcinoma cells via collagen-induced EGR1 expression. J Biol Chem. 2007; 282(7): 4924–4931.
    CrossRefPubMed
  93. Barbolina MV, Moss NM, Westfall SD, et al. Microenvironmental regulation of ovarian cancer metastasis. Cancer Treat Res. 2009; 149: 319–334.
    CrossRefPubMed
  94. Loessner D, Rizzi SC, Stok KS, et al. A bioengineered 3D ovarian cancer model for the assessment of peptidase-mediated enhancement of spheroid growth and intraperitoneal spread. Biomaterials. 2013; 34(30): 7389–7400.
    CrossRefPubMed
  95. Muranen T, Selfors LM, Worster DT, et al. Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer Cell. 2012; 21(2): 227–239.
    CrossRefPubMed
  96. White EA, Kenny HA, Lengyel E. Three-dimensional modeling of ovarian cancer. Adv Drug Deliv Rev. 2014; 79-80: 184–192.
    CrossRefPubMed
  97. Nieman KM, Kenny HA, Penicka CV, et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med. 2011; 17(11): 1498–1503.
    CrossRefPubMed
  98. Zhang Y, Coletta AM, Allen PK, et al. Perirenal adiposity is associated with lower progression-free survival from ovarian cancer. Int J Gynecol Cancer. 2018; 28(2): 285–292.
    CrossRefPubMed
  99. Lawrenson K, Notaridou M, Lee N, et al. In vitro three-dimensional modeling of fallopian tube secretory epithelial cells. BMC Cell Biol. 2013; 14: 43.
    CrossRefPubMed

About cookies

Necessary cookies

Allways active

These cookies are necessary for the proper display and operation of the website. Blocking them may cause the website to malfunction.

Analytical cookies

As part of our website, we use analytical tools, such as Google Analytics, that allow us to verify website traffic. These tools may require the use of cookies.

Community cookies

These are cookies associated with the social networks we use. Accepting them will allow us to associate your visit to the site with our social media profiles.

Marketing cookies

These are cookies responsible for carrying out advertising and marketing activities - consenting to their use will allow us to target you with advertisements based on your previous activities within our website.

Oncology in Clinical Practice

About Via Medica Advertising
Bookstore (Ikamed) TVMed
News
Copyright © 2023 Via Medica Regulations Cookie policy Privacy policy Legal Notice